Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Adam D. Cohen(Penn Center for AIDS Research), Sundar Jagannath(Mount Sinai Hospital), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Yunsi Olyslager(Janssen (Belgium)), Deepu Madduri(Johnson & Johnson (United States)), Myo Htut(City Of Hope National Medical Center), Parameswaran Hari(Medical College of Wisconsin), Jesús G. Berdeja(Tennessee Oncology), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Farah Hossain, John Fastenau(Janssen (United States)), Katharine S. Gries(Johnson & Johnson (United States)), Ross Morrison, Jordan M. Schecter(Centro de Investigación del Cáncer), William Deraedt(Janssen (Belgium)), Lynda Doward, Muhammad Akram(Unknown), S.R. Crawford, Alicia J. Allred(Queen's University Belfast), Marlene J. Carrasco, Carolyn C. Jackson(Centro de Investigación del Cáncer)
Cited by 7
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Awareness and current knowledge of breast cancer
|Biological Research|2017|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k